美国的肌肉骨骼组织工程产品市场 是由出版商Medtech Insight在2010年07月所出版的。
这份英文市场调查报告书包含156 Pages 价格从美金4750起跳。
美国的肌肉骨骼组织工程市场预测在2019年会超过390亿美金。
本报告书内容包括:肌肉骨骼组织工程的概要、目前的生技材料、细胞移植、遗传基因疗法、干细胞、组织重生技术的概要、加入企业的介绍等汇整、内容纲要摘记如下:
实施摘要
第1章 临床概要
- 肌肉骨骼疾病和既存的治疗法
- 关节变形
- 骨质疏松症
- 膝盖损伤
- 韧带・肌腱损伤
- 肩软骨组织裂伤
- 人工骨
第2章 组织工程及组织重生技术
- 生技材料
- 人工生技材料
- 生物学性派生生技材料
- 混合性生技材料
- 遗传基因组织更换生技材料
- 支架
- 血管支架
- 细胞培养技术
- 干细胞技术
- 免疫隔离技术
第3章 组织工程及细胞移植：肌肉骨骼产品市场
- 软骨修复及置换
- 韧带・肌腱修复及置换
- 半月软骨修复及置换
- 骨修复及置换
- 生技材料
- 增殖因素
- 去矿物质骨基质
- 细胞移植
- 遗传基因疗法
- 市场分析
- 竞争分析
第4章 企业介绍
- Histogenics Corporation
- Mesoblast LTD
- NuVasive, Inc.
- Osiris Therapeutics, Inc.
- Osteotech, Inc.
- ProChon Biotech LTD
- TBF Tissue Engineering
- TEI Biosciences, Inc.
- Tepha, Inc.
- TiGenix NV
- Wright Medical Group, Inc.
- Zimmer Holdings, Inc.
附录：企业清册
Abstract
This new report from Medtech Insight analyzes the market potential for tissue
engineering products for musculoskeletal indications. The United States (U.S.)
market for tissue engineering products for musculoskeletal applications is
substantial, with many segments representing multibillion-dollar
opportunities. In the U.S., the total potential market for these products is
expected to exceed $39 billion in the year 2019.
Market segments covered by this report include products for the repair and
replacement of bone, cartilage, ligaments, tendons, and menisci. Product
categories covered include three-dimensional matrices; autologous cultured
chondrocytes; bone grafts and bone substitutes; bone morphogenetic proteins
and other growth factors; cartilage regeneration implants; cell-mediated gene
therapy; ligament, tendon, meniscal, and other soft tissue repair scaffolds;
mesenchymal stem cells; recombinant signaling molecules; and other technology
under development, such as radiofrequency and ultraviolet technology for
cartilage regeneration.
Also provided are analyses of musculoskeletal tissue-engineered products and
competitors and an overview of current biomaterial, cell transplantation, gene
therapy, stem cell, and tissue regeneration technologies, along with disease
incidence and prevalence figures, a review of existing therapies and
treatments, and procedure volumes for the most prevalent musculoskeletal
diseases/disorders.
This Medtech Insight report is the second in a series of reports covering U.S.
tissue engineering markets. Upcoming reports in this series will provide
analyses of U.S. markets for tissue-engineered products for neurologic, organ
regeneration, skin replacement, and urologic applications. The first report in
this series, #A421, “U.S. Markets for Cardiac and Vascular Tissue
Engineering Products,” was published in June 2010.
Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary
and secondary research among the clinicians, researchers, and competitors in
the marketplace, and draw upon the industry expertise of a network of industry
insiders. Medtech Insight exhaustively corroborates the data as a baseline for
completing forward-looking analysis and providing insight into product,
technology and market evolution.
Report Statistics
- 156 Pages
- 24 Exhibits
- 12 Company Profiles
Table of Contents
EXECUTIVE SUMMARY
- i. Overview
- a. Joint Disorders and Treatments
- b. Bone Disorders and Treatments
- ii. Tissue Engineering Technologies
- a. Biomaterials
- b. Cell Culture Technology
- c. Stem Cell Technology
- d. Immunoisolation Technology
- iii. Tissue Engineering and Cell Transplantation: Musculoskeletal Products
Market
- a. Cartilage Repair and Replacement Technologies
- b. Ligament and Tendon Repair and Replacement Technologies
- c. Meniscal Repair and Replacement Technologies
- d. Bone Repair and Replacement Technologies
- e. Market Analysis
- iv. Methodology
- Exhibit ES-1: Tissue Engineering Musculoskeletal Products, Potential
Market Forecast, 2009 and 2019
1. CLINICAL OVERVIEW
- 1.1 Selected Musculoskeletal Disorders and Existing Therapies
- 1.1.1 Joint Degeneration
- 1.1.2 Osteoporosis
- 1.1.3 Knee Injuries
- 1.1.3.1 Articular Cartilage Treatments
- 1.1.3.1.1 Arthroscopy
- 1.1.3.1.1.1 Procedure Volumes
- 1.1.3.1.2 Osteochondral Autografting and Cell Implantation
- 1.1.3.2 Meniscal Injuries
- 1.1.3.2.1 Meniscal Repair and Meniscectomy Procedure Volumes
- 1.1.4 Ligament and Tendon Injuries
- 1.1.4.1 Procedure Volumes
- 1.1.5 Shoulder Soft Tissue Tears
- 1.1.5.1 Rotator Cuff Repair
- 1.1.5.2 Procedure Volumes
- 1.1.6 Bone Grafts
- 1.1.6.1 Bone Grafting Materials
- 1.1.6.1.1 Autografts
- 1.1.6.1.2 Allografts
- 1.1.6.1.3 Other Materials
- 1.1.6.2 Applications
- 1.1.6.2.1 Fracture Repair
- 1.1.6.2.2 Total Joint Surgery
- 1.1.6.2.3 Tumors/Bone Cysts
- 1.1.6.2.4 Spinal Fusion
- 1.1.6.2.5 Vertebroplasty
- 1.1.6.3 Potential Bone Grafting Procedures
- Exhibit 1-1: United States Actual and Projected Population, by Age Group,
Selected Years, 2000-2050
- Exhibit 1-2: Arthroscopic Knee Surgery, Procedure Volumes Forecast,
2009-2014
- Exhibit 1-3: Meniscectomy and Meniscal Repair, Procedure Volumes Forecast,
2009-2014
- Exhibit 1-4: 2009, Meniscectomy and Meniscal Repair, Procedure Volumes, by
Share
- Exhibit 1-5: 2009, Ligament and Tendon Repair and Replacement, Procedure
Volumes, by Share
- Exhibit 1-6: Arthroscopic and Open Anterior Cruciate Ligament Surgery,
Procedure Volumes Forecast, 2009-2014
- Exhibit 1-7: 2009, Bone Grafting in Orthopedic/Spine Surgery, Potential
Procedure Volumes
2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES
- 2.1 Biomaterials
- 2.1.1 Synthetic Biomaterials
- 2.1.2 Biologically Derived Biomaterials
- 2.1.2.1 Collagen
- 2.1.2.2 Xenogeneic Tissue
- 2.1.3 Hybrid Biomaterials
- 2.1.4 Genetically Engineered Biomaterials
- 2.1.4.1 Deoxyribonucleic Acid Transfection Vectors
- 2.1.4.2 Genetically Manipulated Cells
- 2.1.4.3 Three-Dimensional Polymer Technology
- 2.1.4.4 Transgenics
- 2.1.4.5 Fibroblasts
- 2.1.4.6 Immortalized Neural Stem Cells
- 2.1.4.7 Gene-Activated Matrices
- 2.1.5 Scaffolds
- 2.1.6 Vascular Grafts
- 2.2 Cell Culture Technology
- 2.2.1 Bioreactors
- 2.2.1.1 Flatbed Perfusion Systems
- 2.2.1.2 Hollow Fiber Bioreactor Systems
- 2.2.1.3 Cell Suspension Systems
- 2.2.1.4 Disposable Bioreactors
- 2.3 Stem Cell Technology
- 2.3.1 Cell Extraction and Expansion
- 2.3.2 Bioreactors
- 2.4 Immunoisolation Technology
- 2.4.1 Chimeric Immunity
- 2.4.2 Cell Encapsulation Technology
- Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue
Engineering
- Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering
- Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction,
Expansion, and Separation Products and Technologies
3. TISSUE ENGINEERING AND CELL TRANSPLANTATION: MUSCULOSKELETAL PRODUCTS MARKET
- 3.1 Cartilage Repair and Replacement
- 3.1.1 Cell Transplantation Techniques
- 3.1.1.1 Mesenchymal Stem Cells
- 3.1.1.1.1 Mesoblast
- 3.1.1.1.2 Smith & Nephew
- 3.1.1.2 Autologous Chondrocyte Implantation
- 3.1.1.2.1 Ars Arthro Biotechnology/Arthro Kinetics
- 3.1.1.2.2 BioTissue Technologies
- 3.1.1.2.3 CellCoTec
- 3.1.1.2.4 DePuy Mitek with Advanced Technologies and Regenerative
Medicine/Johnson & Johnson
- 3.1.1.2.5 Geistlich Surgery/Geistlich Group
- 3.1.1.2.6 Genzyme Biosurgery/Genzyme
- 3.1.1.2.7 Histogenics
- 3.1.1.2.8 ProChon Biotech
- 3.1.1.2.9 TBF Tissue Engineering
- 3.1.1.2.10 TiGenix
- 3.1.1.2.11 Other Companies
- 3.1.1.3 Allogeneic Juvenile Chondrocytes
- 3.1.1.4 Allograft Plugs
- 3.1.1.5 Genetically Altered Cells
- 3.1.1.6 Ultraviolet Light
- 3.2 Ligament and Tendon Repair and Replacement
- 3.2.1 Bioreactors
- 3.2.2 Scaffolds
- 3.2.2.1 Allogeneic
- 3.2.2.1.1 CryoLife
- 3.2.2.1.2 LifeCell/Kinetic Concepts
- 3.2.2.1.3 RTI Biologics
- 3.2.2.1.4 Wright Medical Technology/Wright Medical Group
- 3.2.2.2 Xenogeneic
- 3.2.2.2.1 Cook Biotech/Cook Group
- 3.2.2.2.2 CryoLife
- 3.2.2.2.3 DePuy/Johnson & Johnson
- 3.2.2.2.4 RTI Biologics
- 3.2.2.3 Collagen
- 3.2.2.3.1 Collagen Matrix
- 3.2.2.3.2 Synovis Life Technologies
- 3.2.2.3.3 TEI Biosciences
- 3.2.2.3.4 Tornier
- 3.2.2.3.5 Zimmer
- 3.2.2.4 Polymeric
- 3.2.2.4.1 Biomet
- 3.2.2.4.2 Organogenesis
- 3.2.2.4.3 Tepha
- 3.2.3 Growth Factors
- 3.2.3.1 Biomet Biologics/Biomet
- 3.2.3.2 Cytomedix
- 3.2.4 Gene Therapy
- 3.3 Meniscal Repair and Replacement
- 3.3.1 Allogeneic Implants
- 3.3.2 Collagen Implants
- 3.3.3 Polymeric Implants
- 3.3.4 Mesenchymal Stem Cells
- 3.3.4.1 Osiris Therapeutics
- 3.3.4.2 University of Pennsylvania
- 3.4 Bone Repair and Replacement
- 3.4.1 Biomaterials
- 3.4.2 Growth Factors
- 3.4.2.1 Recombinant Growth Factors
- 3.4.2.2 LIM Mineralization Protein
- 3.4.2.3 Recombinant Protein UCB-1
- 3.4.2.3.1 Bone Biologics
- 3.4.2.3.2 NellOne Therapeutics
- 3.4.2.4 Bone Morphogenetic Proteins
- 3.4.2.4.1 Medtronic
- 3.4.2.4.2 Stryker
- 3.4.2.4.3 TissueGene
- 3.4.3 Demineralized Bone Matrix
- 3.4.3.1 AlloSource
- 3.4.3.2 Integra LifeSciences
- 3.4.3.3 Kinetic Concepts
- 3.4.3.4 Musculoskeletal Transplant Foundation
- 3.4.3.5 RTI Biologics
- 3.4.4 Cell Transplantation
- 3.4.4.1 Autologous Cells
- 3.4.4.2 Stem Cells
- 3.4.4.2.1 Aastrom Biosciences
- 3.4.4.2.2 Alphatec Holdings with Parcell Laboratories
- 3.4.4.2.3 Cytori Therapeutics
- 3.4.4.2.4 Mesoblast
- 3.4.4.2.5 NuVasive
- 3.4.4.2.6 Orthofix
- 3.4.5 Gene Therapy
- 3.4.5.1 Gene Therapy versus Growth Factors
- 3.4.5.2 Systemic Gene Therapy
- 3.4.5.3 Regional Gene Therapy
- 3.4.5.3.1 Tissue Repair Company/Cardium Therapeutics
- 3.5 Market Analysis
- 3.5.1 Bone Graft Products Market
- 3.5.1.1 Allogeneic Demineralized Bone Matrix Products, Competitive
Analysis
- 3.5.2 Bone Morphogenetic Protein Products Market
- 3.5.3 Market Drivers
- 3.5.4 Market Limiters
- 3.6 Competitive Analysis
- Exhibit 3-1: 2010, Selected Tissue-Engineered Orthopedic Products
- Exhibit 3-2: 2010, Selected Tissue-Engineered Cartilage Repair and
Replacement Products
- Exhibit 3-3: 2010, Selected Tissue-Engineered Ligament and Tendon Repair
and Replacement Products
- Exhibit 3-4: 2010, Selected Meniscal Repair and Replacement Products for
Tissue Engineering Applications
- Exhibit 3-5: 2010, Selected Bone Repair Products for Tissue Engineering
Applications
- Exhibit 3-6: 2010, Selected Bone Void Fillers/Bone Replacement Materials
for Tissue Engineering Applications
- Exhibit 3-7: Comparison of Growth Factors and Gene Therapy for Bone Repair
- Exhibit 3-8: Gene Therapy Delivery Methods for Bone Repair
- Exhibit 3-9: Tissue Engineering Musculoskeletal Products, Potential Market
Forecast, 2009 and 2019
- Exhibit 3-10: 2009, Bone Grafts and Bone Substitutes Market
- Exhibit 3-11: 2009, Allogeneic Demineralized Bone Matrix Products, Share
by Supplier
- Exhibit 3-12: Bone Morphogenetic Protein Products, Market Forecast,
2009-2014
- Exhibit 3-13: Tissue Engineering Musculoskeletal Products, Product
Introduction Forecast, by Indication, 2014 and 2019
4. COMPANY PROFILES
- 4.1 Histogenics Corporation
- 4.2 Mesoblast LTD
- 4.3 NuVasive, Inc.
- 4.4 Osiris Therapeutics, Inc.
- 4.5 Osteotech, Inc.
- 4.6 ProChon Biotech LTD
- 4.7 TBF Tissue Engineering
- 4.8 TEI Biosciences, Inc.
- 4.9 Tepha, Inc.
- 4.10 TiGenix NV
- 4.11 Wright Medical Group, Inc.
- 4.12 Zimmer Holdings, Inc.
APPENDIX: COMPANY LISTING
|
